Search - tctmd.com

Displaying 361 - 380 of 1942

Sort: Relevancy | Date

Presentation TCT 2022

TCT 36: Complete revascularization versus culprit lesion only PCI in patients with diabetes mellitus and multivessel coronary artery disease: A subgroup analysis of the COMPLETE trial

Presenter: Zardasht Oqab

September 17, 2022

TCT 35: Effects of Complete Revascularization According to Age in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel: Insights from the COMPLETE Trial

Presentation TCT 2022

TCT 35: Effects of Complete Revascularization According to Age in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel: Insights from the COMPLETE Trial

Presenter: Kevin Bainey

September 17, 2022

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

News Daily News

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

September 15, 2022

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

ESC Revamps Guidelines on Ventricular Arrhythmias, Sudden Cardiac Death

News Conference News ESC 2022

ESC Revamps Guidelines on Ventricular Arrhythmias, Sudden Cardiac Death

September 02, 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

Smartphone App Can Detect AF, Influence Care: eBRAVE-AF

News Conference News ESC 2022

Smartphone App Can Detect AF, Influence Care: eBRAVE-AF

August 30, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

News Conference News ESC 2022

Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration

Michael O'Riordan

August 29, 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

August 27, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

First Cardio-Oncology Guidelines From ESC Cover ‘Tremendous’ Territory

News Conference News ESC 2022

First Cardio-Oncology Guidelines From ESC Cover ‘Tremendous’ Territory

August 26, 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

News Conference News ESC 2022

Polypill Bests Usual Care in Patients With Recent MI: SECURE

Michael O'Riordan

August 26, 2022

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

August 23, 2022

What’s Going to Be Hot at ESC 2022?

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

August 22, 2022

Steep Rise in PVAD Support for Protected PCI: Medicare Data

News Daily News

Steep Rise in PVAD Support for Protected PCI: Medicare Data

August 19, 2022

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

News Daily News

Even With Revascularization in ISCHEMIA, Skipping Meds Hurt Health Status

August 19, 2022

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Intermittent Fasting Trial Comes Out (Partly) Positive, but CV Impact Mixed

News Daily News

Intermittent Fasting Trial Comes Out (Partly) Positive, but CV Impact Mixed

August 12, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.